Preferences help
enabled [disable] Abstract
Number of results
2010 | 57 | 4 | 547-552
Article title

Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study

Title variants
Languages of publication
Background. There is evidence that dyslipidemia is associated with chronic kidney disease (CKD) and it has been implicated in the progression of renal damage. Optimal management of dyslipidemia should therefore lead to renal benefits. A number of experimental models demonstrate a beneficial effect of statins in ameliorating renal damage. However, the exact mechanism by which statins protect against renal damage remains unclear. Methods. In a placebo-controlled, randomized, cross-over study we evaluated the influence of atorvastatin (ATO) 40 mg/day added to the renin-angiotensin-aldosterone systeme (RAAS) blockade on proteinuria and surrogate biomarkers of tubular damage or injury in 14 non-diabetic patients with proteinuria (0.4-1.8 g per 24 h) with normal or declined kidney function (eGFR 55-153 ml/min). In the eight-week run-in period, therapy using angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: ATO/washout/placebo or placebo/washout/ATO. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. The primary end point of this study was a change in proteinuria measured as 24-h urine protein excretion (DPE). Secondary end points included urine N-acetyl-β-d-glucosaminidase (NAG) and α1-microglobulin (α1m) excretion. Results. The ATO therapy significantly reduced urine excretion of α1m (p=0.033) and NAG (p=0.038) as compared to placebo. There were no differences in proteinuria, blood pressure, eGFR and serum creatinine between the ATO and placebo groups. Conclusion. Atorvastatin treatment is safe and improves biomarkers of tubular damage or injury in non-diabetic patients with CKD.
Physical description
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
  • Blood Brain Barrier and Neuro-Oncology Program, Oregon Health & Science University, Portland, Oregon, USA
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
  • Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Medical University of Gdansk, Gdansk, Poland
  • Department of Clinical Nutrition and Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland
  • Department of Clinical Nutrition and Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
  • Kidney Disease Outcomes Quality Initiative (K/DOQI) Group (Corporate Author) (2003) K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41 (4 Suppl 3): I-IV, S1-S91.
  • Arici M, Walls J (2001) End-stage renal disease atherosclerosis and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 59: 407-14.
  • Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J (2009) Time for new indications for statins? Med Sci Monit 15: MS1-MS5.
  • Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D'Amico G (2002) Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 17: 1890-1896.
  • Bianchi S, Bigazzi R, Caiazza A, Campese VM (2003) A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-70.
  • Chan PC, Robinson JD, Yeung WC, Cheng IK, Yeung HW, Tsang MT (1992) Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7: 93-99.
  • Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB (2002) Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39: 1213-1217.
  • Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
  • Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, Stijnen T, Hofman A, Schram MT, Witteman JC (2007) Genetic variation C-reactive protein levels and incidence of diabetes. Diabetes 56: 872-878.
  • Deslypere JP, Delanghe J, Vermeulen A (1990) Proteinuria as complication of simvastatin treatment. Lancet 336: 1453.
  • Epstein MV, Campese M (2005) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45: 2-14.
  • Fathi R, Isbel N, Short L, Haluska B, Johnson D, Marwick TH (2004) The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43: 45-52.
  • Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59: 260-269.
  • Fuiano G, Esposito C, Sepe V, Colucci G, Bovino M, Rosa M, Balletta M, Bellinghieri G, Conte G, Cianciaruso B, Dal Canton A (1996) Effects of hypercholesterolemia of renal hemodynamics: study in patients with nephrotic syndrome. Nephron 73: 430-435.
  • Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gomez-Campdera F, Vega A, Abad S, Luno J (2006) Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 17 (12 Suppl 3): S231-S235.
  • Guijarro CW, Keane F (1993) Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 2: 372-379.
  • Holdt-Lehmann B, Lehmann A, Korten G, Nagel H, Nizze H, Schuff-Werner P (2000) Diagnostic value of urinary alanine aminopeptidase and N-acetyl-β-d-glucosaminidase in comparison to α1-microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 297: 93-102.
  • Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T (2002) Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17: 1513-1517.
  • Keane WF, Kasiske BL, O'Donnell MP (1988) Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 47: 157-160.
  • Maroni BJ, Steinman TI, Mitch WE (1985) A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27: 58-65.
  • Maruhn D (1976) Rapid calorimetric assay of β-galactosidase and N-acetyl-β-d-glucosaminidase in human urine. Clin Chim Acta 73: 453-461.
  • McKenney JM, Davidson MH, Jacobson TA, Guyton JR (2006) Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97: 89C-94C.
  • Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K (2006) Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 26: 82-86.
  • Newman C, Tsai J, Szarek M, Luo D, Gibson E (2006) Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiol 97: 61-67.
  • Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH (2008) The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) Diab Vasc Dis Res 5: 177-183.
  • Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P (2005) Statin therapy LDL cholesterol C-reactive protein and coronary artery disease. N Engl J Med 352: 29-38.
  • Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, Taccola D, Donadio C, Tramonti G, Innocenti M, Casto G, Consani C, Sbragia G, Franzoni F, Galetta F, Panicucci E, Barsotti G (2006) In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 21: 337-344.
  • Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein interleukin 6 and risk of developing type 2 diabetes mellitus. Jama 286: 327-334.
  • Renke M, Knap N, Tylicki L, Rutkowski P, Neuwelt A, Larczynski W, Wozniak M, Rutkowski B (2010a) Atorvastatin attenuates oxidative stress in patients with chronic kidney disease. Med Sci Monit 16: LE3-LE3.
  • Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Lysiak-Szydlowska W, Wozniak M, Rutkowski B (2010b) Effect of pentoxifylline on proteinuria markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled randomized cross-over study. Acta Biochim Pol 57: 119-123.
  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28.
  • Rutkowski B, Szolkiewicz M, Korczynska J, Sucajtys E, Stelmanska E, Nieweglowski T, Swierczynski J (2003) The role of lipogenesis in the development of uremic hyperlipidemia. Am J Kidney Dis 41 (3 Suppl 1): S84-S88.
  • Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12: 1908-1915.
  • Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17: 2006-2016.
  • Shurraw SM, Tonelli M (2006) Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 26: 523-539.
  • Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. Bmj 336: 645-651.
  • Tonelli M (2006) The effect of statins on preservation of kidney function in patients with coronary artery disease. Curr Opin Cardiol 21: 608-612.
  • Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563.
  • Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68: 237-245.
  • Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A (2008) Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 180: 2212-2217.
  • Tylicki L, Rutkowski B, Horl WH (2003) Antioxidants: a possible role in kidney protection. Kidney Blood Press Res 26: 303-314.
  • Verhulst A, D'Haese PC, De Broe ME (2004) Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15: 2249-2257.
  • Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S (2004) Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 43: 471-478.
  • Zoja C, Abbate M, Remuzzi G (2006) Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens 15: 250-257.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.